Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
ramucirumab
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Study of Docetaxel + IMC-1121B or Placebo in Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0606
, TRI0-CIRG-012, TRI0-012, EUDRACT Number: 2008-001727-65, NCT00703326
2.
Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0715
, Eudract 2008-005964-15, NCT00917384
3.
Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP18-0601
, NCT00683475
4.
A First-line Study of IMC-1121B With Paclitaxel and Carboplatin in Stage IIIB/IV Non-small Cell Lung Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0708
, EudraCT #2007-006715-22, NCT00735696
5.
Study of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin Chemotherapies in Patients With Colorectal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0709
, EudraCT #2008-004936-19, NCT00862784
6.
Phase II Study of Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Patients With Recurrent Glioblastoma Multiforme
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0901
, ABTC 0901, IMCL-CP-19-0801, NCT00895180
7.
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0712
, NCT01017731
8.
Study of IMC-1121B in Patients With Advanced Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
20 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CP12-0816
, NCT01005355
Select All on Page
Help with Results
